» Articles » PMID: 33517897

Pan-cancer Detection of Driver Genes at the Single-patient Resolution

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2021 Feb 1
PMID 33517897
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Identifying the complete repertoire of genes that drive cancer in individual patients is crucial for precision oncology. Most established methods identify driver genes that are recurrently altered across patient cohorts. However, mapping these genes back to patients leaves a sizeable fraction with few or no drivers, hindering our understanding of cancer mechanisms and limiting the choice of therapeutic interventions.

Results: We present sysSVM2, a machine learning software that integrates cancer genetic alterations with gene systems-level properties to predict drivers in individual patients. Using simulated pan-cancer data, we optimise sysSVM2 for application to any cancer type. We benchmark its performance on real cancer data and validate its applicability to a rare cancer type with few known driver genes. We show that drivers predicted by sysSVM2 have a low false-positive rate, are stable and disrupt well-known cancer-related pathways.

Conclusions: sysSVM2 can be used to identify driver alterations in patients lacking sufficient canonical drivers or belonging to rare cancer types for which assembling a large enough cohort is challenging, furthering the goals of precision oncology. As resources for the community, we provide the code to implement sysSVM2 and the pre-trained models in all TCGA cancer types ( https://github.com/ciccalab/sysSVM2 ).

Citing Articles

SSCI: Self-Supervised Deep Learning Improves Network Structure for Cancer Driver Gene Identification.

Xu J, Hao J, Liao X, Shang X, Li X Int J Mol Sci. 2024; 25(19).

PMID: 39408682 PMC: 11476395. DOI: 10.3390/ijms251910351.


ECD-CDGI: An efficient energy-constrained diffusion model for cancer driver gene identification.

Wang T, Zhuo L, Chen Y, Fu X, Zeng X, Zou Q PLoS Comput Biol. 2024; 20(8):e1012400.

PMID: 39213450 PMC: 11392234. DOI: 10.1371/journal.pcbi.1012400.


Personalized Driver Gene Prediction Using Graph Convolutional Networks with Conditional Random Fields.

Wei P, Zhu A, Cao R, Zheng C Biology (Basel). 2024; 13(3).

PMID: 38534453 PMC: 10968662. DOI: 10.3390/biology13030184.


Prediction of cancer driver genes and mutations: the potential of integrative computational frameworks.

Nourbakhsh M, Degn K, Saksager A, Tiberti M, Papaleo E Brief Bioinform. 2024; 25(2).

PMID: 38261338 PMC: 10805075. DOI: 10.1093/bib/bbad519.


Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.

Liu W, Wang H, Zhao Q, Tao C, Qu W, Hou Y Cancer Commun (Lond). 2023; 44(2):226-250.

PMID: 38143235 PMC: 10876206. DOI: 10.1002/cac2.12513.


References
1.
DAntonio M, Ciccarelli F . Integrated analysis of recurrent properties of cancer genes to identify novel drivers. Genome Biol. 2013; 14(5):R52. PMC: 4054099. DOI: 10.1186/gb-2013-14-5-r52. View

2.
Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

3.
Leiserson M, Vandin F, Wu H, Dobson J, Eldridge J, Thomas J . Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2014; 47(2):106-14. PMC: 4444046. DOI: 10.1038/ng.3168. View

4.
Morgan M, Shilatifard A . Chromatin signatures of cancer. Genes Dev. 2015; 29(3):238-49. PMC: 4318141. DOI: 10.1101/gad.255182.114. View

5.
Reimand J, Bader G . Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol. 2013; 9:637. PMC: 3564258. DOI: 10.1038/msb.2012.68. View